ViiV Healthcare Limited

ViiV Healthcare Limited is a global specialist HIV company, established in 2009 as a joint venture by GlaxoSmithKline (GSK) and Pfizer, with Shionogi joining as a shareholder in 2012. Headquartered in the United Kingdom, ViiV Healthcare is dedicated exclusively to the development and delivery of innovative HIV treatments and care. The company’s mission is to ensure that no one living with HIV is left behind, focusing on both scientific advancement and community engagement.

ViiV Healthcare’s approach to lobbying within the European Union centers on influencing policy and regulatory frameworks to improve access to HIV medicines, promote research and development, and foster a supportive environment for people living with HIV. The company is accredited with the EU Transparency Register, reflecting its commitment to openness and ethical engagement with EU institutions. ViiV Healthcare’s lobbying activities are characterized by direct engagement with policymakers, participation in advisory boards, and collaboration with patient advocacy groups and other stakeholders.

The company’s lobbying priorities include securing favorable regulatory pathways for new HIV treatments, advocating for policies that support innovation, and ensuring that the needs of people living with HIV are represented in EU health policy discussions. ViiV Healthcare also works to address barriers to access and to reduce stigma associated with HIV/AIDS. Its efforts extend to supporting community-based organizations, funding advocacy initiatives, and participating in multi-stakeholder platforms.

ViiV Healthcare’s transparency is further demonstrated by its public disclosure of clinical trial data, grants, and donations. The company regularly publishes reports on its interactions with healthcare professionals, organizations, and EU institutions. Through its lobbying and networking activities, ViiV Healthcare aims to shape a policy environment that accelerates the development and uptake of life-saving HIV treatments across Europe

Legal Name: ViiV Healthcare Limited
EU Transparency Register ID: 062557939516-27
Head Office: United Kingdom
Year Established: 2009
Ownership: Majority-owned by GSK, with Pfizer and Shionogi as shareholders
Main Focus: HIV treatment and care

No related lobbyists found.

Pharmaceutical industry
HIV/AIDS treatment and prevention
Health policy and regulation
Research and innovation
Patient advocacy

ViiV Healthcare Limited networks and collaborates with a range of organizations, including:

European AIDS Treatment Group (EATG) – Joint participation in advisory boards and community initiatives.
Gilead Sciences, Merck Sharp & Dohme – Collaborative meetings and policy discussions on HIV treatment and access.
Patient advocacy groups and NGOs – Funding and joint projects to support people living with HIV and promote access to care.
– Co-sponsorship of clinical trials and research initiatives.
– Parent company and strategic partner.
– Shareholders and partners in R&D and policy engagement

The EU Transparency Register requires reporting of lobbying expenditures in ranges. ViiV Healthcare Limited’s reported annual lobbying expenses in the EU are as follows:

Year	Lobbying Costs (EUR)
2019	400,000 – 499,999
2020	400,000 – 499,999
2021	400,000 – 499,999
2022	400,000 – 499,999
2023	400,000 – 499,999
2024	400,000 – 499,999

Total estimated lobbying costs since registration: 2,400,000 – 2,999,994 EUR

European Medicines Agency (EMA)
Directorate-General for Health and Food Safety (DG SANTE)
Other relevant EU health and research bodies

The following are known meetings and participations involving ViiV Healthcare Limited:

: Meeting with MEP Nicolás González Casares, as published in the European Parliament’s register of meetings.
: Participation in the European Community Advisory Board (ECAB) meeting on HIV with EATG, Merck Sharp & Dohme, and Gilead Sciences in Istanbul.
: Participation in ECAB meeting with EATG and Gilead Sciences in Warsaw.
: Regular engagement with EU institutions and participation in conferences, advisory boards, and policy forums